Cost-effectiveness analysis of a pharmacy asthma care program in Australia

Gordois, A., Armour, C., Brillant, M., Bosnic-Anticevich, S., Burton, D., Emmerton, L. M., Krass, I., Saini, B., Smith, L. and Stewart, K. (2007) Cost-effectiveness analysis of a pharmacy asthma care program in Australia. Disease Management & Health Outcomes, 15 6: 387-396. doi:10.2165/00115677-200715060-00006

Author Gordois, A.
Armour, C.
Brillant, M.
Bosnic-Anticevich, S.
Burton, D.
Emmerton, L. M.
Krass, I.
Saini, B.
Smith, L.
Stewart, K.
Title Cost-effectiveness analysis of a pharmacy asthma care program in Australia
Journal name Disease Management & Health Outcomes   Check publisher's open access policy
ISSN 1173-8790
Publication date 2007
Sub-type Article (original research)
DOI 10.2165/00115677-200715060-00006
Volume 15
Issue 6
Start page 387
End page 396
Total pages 10
Editor R. Stather
Place of publication New Zealand
Publisher Adis International
Collection year 2008
Language eng
Subject C1
321217 Health Counselling
730300 Health and Support Services
111717 Primary Health Care
110203 Respiratory Diseases
Abstract Objectives: A pharmacy asthma care program in Australia, which included specific education on asthma and asthma medication, trigger factors, use of inhalers, and medication adherence, as well as goal setting and patient review aspects, assessed the impact of a community pharmacy asthma service on the severity of patients' asthma over 6 months. Data from this study were used to estimate the cost effectiveness of the program. Methods: The intervention population was compared with a control population and results at 6 months were included in a Markov model in order to estimate the cost effectiveness over 5 years from the perspective of the Australian healthcare system. The model had a cycle length of 6 months and included transition probabilities for switching between classes of severity of asthma, the costs of asthma treatment and program delivery, and utility values for a patient's quality of life with asthma. Costs were Australian dollars ($A), year 2006 values, and both costs and benefits were discounted at a rate of 5% per annum. Results: Over the 5 years following an initial review, the program generated 0.131 additional quality-adjusted life-years (QALYs), at an additional net cost of $A623 if annual reviews were required to maintain asthma improvements (annual review scenario) or $A376 if annual reviews were not required (no annual review scenario), resulting in costs per QALY gained of $A4753 and $A2869, respectively. Conclusions: The program appears to be cost effective compared with no program, whether or not annual reviews were required to maintain improvements and under a range of other assumptions. Current evidence suggests that the pharmacy asthma care program should be implemented and funded for the treatment of adults with asthma in Australia.
Keyword Asthma
Cost utility
Pharmaceutical care programmes
Q-Index Code C1
Q-Index Status Confirmed Code

Document type: Journal Article
Sub-type: Article (original research)
Collections: Excellence in Research Australia (ERA) - Collection
2008 Higher Education Research Data Collection
School of Pharmacy Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 9 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 15 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Thu, 01 May 2008, 09:36:49 EST by Elizabeth Pyke on behalf of School of Pharmacy